{
    "root": "3953e8ee-89f6-4455-9551-e6bddf5bf6be",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Fenofibrate",
    "value": "20250509",
    "ingredients": [
        {
            "name": "FENOFIBRATE",
            "code": "U202363UOS"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "SOYBEAN LECITHIN",
            "code": "1DI56QDM62"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "fenofibrate tablets peroxisome proliferator receptor alpha ( pparα ) activator indicated adjunct diet : • reduce elevated ldl-c , total-c , tg apo b , increase hdl-c adult patients primary hypercholesterolemia mixed dyslipidemia ( 1.1 ) . • treatment adult patients severe hypertriglyceridemia ( 1.2 ) . important limitations : fenofibrate shown reduce coronary heart disease morbidity mortality patients type 2 diabetes mellitus ( 5.1 ) .",
    "contraindications": "• primary hypercholesterolemia mixed dyslipidemia : initial dose 145 mg daily ( 2.2 ) . • severe hypertriglyceridemia : initial dose 48 145 mg daily . maximum dose 145 mg ( 2.3 ) . • renally impaired patients : initial dose 48 mg daily ( 2.4 ) . • geriatric patients : select dose basis renal function ( 2.5 ) • maybe taken without regard meals ( 2.1 ) .",
    "warningsAndPrecautions": "fenofibrate tablets , usp available ; 145 mg tablets white off-white , oval , biconvex film coated tablets , debossed ' j ' one side '136 ' side , available : bottles 30 tablets ndc 68788-8106-3bottles 60 tablets ndc 68788-8106-6 bottles 90 tablets ndc 68788-8106-9bottles 100 tablets ndc 68788-8106-1storage store 20o 25oc ( 68o 77o f ) [ usp controlled room temperature ] . keep reach children . protect moisture .",
    "adverseReactions": "fenofibrate tablets contraindicated : • patients severe renal impairment , including receiving dialysis [ pharmacology ( 12.3 ) ] . • patients active liver disease , including primary biliary cirrhosis unexplained persistent liver function abnormalities [ ( 5.3 ) ] . • patients preexisting gallbladder disease [ ( 5.5 ) ] . • nursing mothers [ ( 8.3 ) ] . • patients known hypersensitivity fenofibrate fenofibric acid [ ( 5.9 ) ] .",
    "indications_original": "Fenofibrate tablets are peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: • To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.1 ). • For treatment of adult patients with severe hypertriglyceridemia ( 1.2 ). Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 5.1 ).",
    "contraindications_original": "• Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 145 mg once daily ( 2.2 ). • Severe hypertriglyceridemia: Initial dose of 48 to 145 mg once daily. Maximum dose is 145 mg ( 2.3 ). • Renally impaired patients: Initial dose of 48 mg once daily ( 2.4 ). • Geriatric patients: Select the dose on the basis of renal function ( 2.5 ) • Maybe taken without regard to meals ( 2.1 ).",
    "warningsAndPrecautions_original": "Fenofibrate tablets, USP are available in;145 mg tablets are white to off-white, oval, biconvex film coated tablets, debossed with 'J' on one side and '136' on other side, available in:Bottles of 30 Tablets                                                                     NDC 68788-8106-3Bottles of 60 Tablets                                                                     NDC 68788-8106-6\n                  Bottles of 90 Tablets                                                                     NDC 68788-8106-9Bottles of 100 Tablets                                                                   NDC 68788-8106-1Storage Store at 20o to 25oC (68o to 77o F) [See USP Controlled Room Temperature]. Keep out of reach of children. Protect from moisture.",
    "adverseReactions_original": "Fenofibrate tablets are contraindicated in: \n                     • patients with severe renal impairment, including those receiving dialysis [see Clinical Pharmacology (12.3)].  \n                     • patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Warnings and Precautions (5.3)].\n                     \n                     • patients with preexisting gallbladder disease [see Warnings and Precautions (5.5)]. \n                     \n                     • nursing mothers [see Use in Specific Populations (8.3)].\n                     \n                     • patients with known hypersensitivity to fenofibrate or fenofibric acid [see Warnings and Precautions(5.9)]."
}